A community-based study of Helicobacter pylori therapy using the strategy of test, treat, retest, and re-treat initial treatment failures

Helicobacter

Volumn 11, Issue 5, 2006, Pages 418-424

  Lee, Yi Chia ^a,b   Wu, Hui Min ^a   Chen, Tony Hsiu Hsi ^a   Liu, Tzeng Ying ^c   Chiu, Han Mo ^a,b   Chang, Chun Chao ^d   Wang, Hsiu Po ^b   Wu, Ming Shiang ^b   Chiang, Hung ^e   Wu, Meng Chen ^e   Lin, Jaw Town ^b,f  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c Health Bureau of Lienchiang County   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e Taipei Institute of Pathology   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Antibiotic regimen; Gastric cancer; Helicobacter pylori; Population based study

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CLARITHROMYCIN; ESOMEPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; OMEPRAZOLE; TINIDAZOLE;

ADULT; ARTICLE; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DYSPEPSIA; ERADICATION THERAPY; FEMALE; FOLLOW UP; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LOOSE FECES; MAJOR CLINICAL STUDY; MALAISE; MALE; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RASH; TASTE DISORDER; TREATMENT FAILURE; UREA BREATH TEST;

ANTI-BACTERIAL AGENTS; DELIVERY OF HEALTH CARE; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; OFLOXACIN; TREATMENT FAILURE; TREATMENT OUTCOME;

HELICOBACTER PYLORI;

EID: 33748461592     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2006.00432.x     Document Type: Article

References (33)

1. Department of Health. Main causes of death by cancer in Taiwan. Taipei, Taiwan: Department of Health, Executive Yuan, 2004.
2. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process - First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992;52:6735-40.
3. Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998;114:1169-79.
4. Eslick GD, Lim LL, Byles JE, Xia HH, Talley NJ. Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis. Am J Gastroenterol 1999;94:2373-9.
5. Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004;291:187-94.
6. Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167-80.
7. Ducons JA, Santolaria S, Guirao R, Ferrero M, Montoro M, Gomollon F. Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer. Aliment Pharmacol Ther 1999;13:775-80.
8. Vergara M, Vallve M, Gisbert JP, Calvet X. Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2003;18:647-54.
9. Poon SK, Chang CS, Su J, Lai CH, Yang CC, Chen GH, Wang WC. Primary resistance to antibiotics and its clinical impact on the efficacy of Helicobacter pylori lansoprazole-based triple therapies. Aliment Pharmacol Ther 2002;16:291-6.
10. Hojo M, Miwa H, Nagahara A, Sato N. Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scand J Gastroenterol 2001;36:690-700.
11. Langtry HD, Lamb HM. Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract. Drugs 1998;56:487-515.
12. Cammarota G, Cianci R, Cannizzaro O, et al. Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther 2000;14:1339-43.
13. Bilardi C, Dulbecco P, Zentilin P, et al. A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial. Clin Gastroenterol Hepatol 2004;2:997-1002.
14. Nista EC, Candelli M, Cremonini F, et al. Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. Aliment Pharmacol Ther 2003;18:627-33.
15. Saad RJ, Schoenfeld P, Kim HM, Chey WD. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol 2006;101:488-96.
16. Chen TH, Chiu YH, Luh DL, et al. Taiwan community-based multiple screening model: design, implementation, and analysis of 42,387 participants. Cancer 2004;100:1734-43.
17. Chen TS, Chang FY, Chen PC, Huang TW, Ou JT, Tsai MH, Wu MS, Lin JT. Simplified 13C-urea breath test with a new infrared spectrometer for diagnosis of Helicobacter pylori infection. J Gastroenterol Hepatol 2003;18:1237-43.
18. Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998;13:1-12.
19. Gail MH, You WC, Chang YS, et al.Factorial trial of three interventions to reduce the progression of precancerous gastric lesions in Shandong, China: design issues and initial data. Control Clin Trials 1998;19:352-69.
20. Sung JJ, Lin SR, Ching JY, et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology 2000;119:7-14.
21. Moayyedi P, Feltbower R, Crocombe W, Mason S, Atha P, Brown J, Dowell AC, Richards ID, Axon AT. The effectiveness of omeprazole, clarithromycin and tinidazole in eradicating Helicobacter pylori in a community screen and treat programme. Leeds Help Study Group. Aliment Pharmacol Ther 2000;14:719-28.
22. Peterson WL, Fendrick AM, Cave DR, Peura DA, Garabedian-Ruffalo SM, Laine L. Helicobacter pylori-related disease: guidelines for testing and treatment. Arch Intern Med 2000;160:1285-91.
23. Qasim A, O'Morain CA. Review article: treatment of Helicobacter pylori infection and factors influencing eradication. Aliment Pharmacol Ther 2002;16:24-30.
24. Megraud F, Lamouliatte H. Review article: the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2003;17:1333-43.
25. Gisbert JP, Pajares JM. Helicobacter pylori 'rescue' therapy after failure of two eradication treatments. Helicobacter 2005;10:363-72.
26. Chi CH, Lin CY, Sheu BS, Yang HB, Huang AH, Wu JJ. Quadruple therapy containing amoxicillin and tetracycline is an effective regimen to rescue failed triple therapy by overcoming the antimicrobial resistance of Helicobacter pylori. Aliment Pharmacol Ther 2003;18:347-53.
27. Qasim A, Sebastian S, Thornton O, Dobson M, McLoughlin R, Buckley M, O'Connor H, O'Morain C. Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients. Aliment Pharmacol Ther 2005;21:91-6.
28. Huang AH, Sheu BS, Yang HB, Huang CC, Wu JJ, Lin XZ. Impact of Helicobacter pylori antimicrobial resistance on the outcome of 1-week lansoprazole-based triple therapy. J Formos Med Assoc 2000;99:704-9.
29. Wong WM, Gu Q, Lam SK, et al. Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment Pharmacol Ther 2003;17:553-60.
30. Perri F, Festa V, Clemente R, Villani MR, Quitadamo M, Caruso N, Bergoli ML, Andriulli A. Randomized study of two 'rescue' therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am J Gastroenterol 2001;96:58-62.
31. Wong WM, Wong BC, Lu H, et al. One-week omeprazole, furazolidone and amoxicillin rescue therapy after failure of Helicobacter pylori eradication with standard triple therapies. Aliment Pharmacol Ther 2002;16:793-8.
32. Bosques-Padilla FJ, Garza-Gonzalez E, Calderon-Lozano IE, Reed-SanRoman G, de Arino Suarez M, Valdovinos-Diaz MA, Orozco-Gamiz A, Blancas-Valencia JM, Tamayo-de la Cuesta JL. Open, randomized multicenter comparative trial of rabeprazole, ofloxacin and amoxicillin therapy for Helicobacter pylori eradication: 7 vs. 14 day treatment. Helicobacter 2004;9:417-21.
33. De Francesco V, Della Valle N, Stoppino V, Amoruso A, Muscatiello N, Panella C, Ierardi E. Effectiveness and pharmaceutical cost of sequential treatment for Helicobacter pylori in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther 2004;19:993-8.